Menu Search
Equities

Catalyst Pharmaceuticals Inc

CN2:BRN

Catalyst Pharmaceuticals Inc

Actions
  • Price (CHF)14.94
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Mar 05 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Catalyst Pharmaceuticals Inc had net income fall -14.05% from 83.08m to 71.41m despite a 85.90% increase in revenues from 214.20m to 398.20m. An increase in the selling, general and administrative costs as a percentage of sales from 27.16% to 33.58% was a component in the falling net income despite rising revenues.
Gross margin86.32%
Net profit margin31.01%
Operating margin37.78%
Return on assets24.10%
Return on equity28.29%
Return on investment27.94%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Catalyst Pharmaceuticals Inc fell by 160.76m. However, the company earned 143.60m from its operations for a Cash Flow Margin of 36.06%. In addition the company used 293.50m on investing activities and also paid 10.86m in financing cash flows.
Cash flow per share1.48
Price/Cash flow per share15.83
Book value per share5.54
Tangible book value per share4.15
More ▼

Balance sheet in USDView more

Catalyst Pharmaceuticals Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio5.11
Quick ratio4.92
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		123.05
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.